Avecho Biotechnology Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Avecho Biotechnology has a total shareholder equity of A$4.2M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$5.9M and A$1.6M respectively.

Belangrijke informatie

Verhouding schuld/eigen vermogen

AU$0

Schuld

Rente dekkingsratio	n/a
Contant	AU$4.84m
Aandelen	AU$4.22m
Totaal verplichtingen	AU$1.65m
Totaal activa	AU$5.86m

Recente financiële gezondheidsupdates

Companies Like Avecho Biotechnology (ASX:AVE) Are In A Position To Invest In Growth

Jan 13

Recent updates

Companies Like Avecho Biotechnology (ASX:AVE) Are In A Position To Invest In Growth

Jan 13

Here's Why We're Watching Avecho Biotechnology's (ASX:AVE) Cash Burn Situation

May 31

Avecho Biotechnology (ASX:AVE) Is In A Good Position To Deliver On Growth Plans

Nov 04

We're Hopeful That Avecho Biotechnology (ASX:AVE) Will Use Its Cash Wisely

Jul 14

We Think Avecho Biotechnology (ASX:AVE) Can Afford To Drive Business Growth

Mar 23

We're Not Very Worried About Avecho Biotechnology's (ASX:AVE) Cash Burn Rate

Dec 08

Analyse van de financiële positie

Kortlopende schulden: AVE's short term assets (A$5.6M) exceed its short term liabilities (A$1.6M).

Langlopende schulden: AVE's short term assets (A$5.6M) exceed its long term liabilities (A$58.8K).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: AVE is debt free.

Schuld verminderen: AVE has not had any debt for past 5 years.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: AVE has sufficient cash runway for more than a year based on its current free cash flow.

Voorspelling contante baan: AVE has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 15.4% each year.

Avecho Biotechnology Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Companies Like Avecho Biotechnology (ASX:AVE) Are In A Position To Invest In Growth

Here's Why We're Watching Avecho Biotechnology's (ASX:AVE) Cash Burn Situation

Avecho Biotechnology (ASX:AVE) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Avecho Biotechnology (ASX:AVE) Will Use Its Cash Wisely

We Think Avecho Biotechnology (ASX:AVE) Can Afford To Drive Business Growth

We're Not Very Worried About Avecho Biotechnology's (ASX:AVE) Cash Burn Rate

Recent updates

First half 2024 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in 1H 2023)

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2022)

Avecho Biotechnology Limited, Annual General Meeting, May 30, 2024

New major risk - Shareholder dilution

Avecho Biotechnology Limited has completed a Follow-on Equity Offering in the amount of AUD 6.04685 million.

First half 2023 earnings released: AU$0.001 loss per share (vs AU$0 in 1H 2022)

Full year 2022 earnings released: AU$0.001 loss per share (vs AU$0.002 loss in FY 2021)

Companies Like Avecho Biotechnology (ASX:AVE) Are In A Position To Invest In Growth

Athenex Submits Avecho's Phytonadione to FDA Pre-IND

Avecho Biotechnology Limited Receives Ethics Approval for its Pivotal Phase III Clinical Trial Testing its Oral CBD Softgel Capsule for Insomnia

Less than half of directors are independent

Avecho Biotechnology Limited Announces Interim Results from Comparative Pharmacokinetic Studies Conducted in the Uk

First half 2022 earnings released: EPS: AU$0 (vs AU$0.001 loss in 1H 2021)

Here's Why We're Watching Avecho Biotechnology's (ASX:AVE) Cash Burn Situation

Less than half of directors are independent

Avecho Biotechnology Limited Announces Positive Results for Its Phase IIa Study

Avecho Biotechnology Limited Announces Dosing Commencement for CBD Topical Osteoarthritis Study in collaboration with the Lambert Initiative

Full year 2021 earnings: Revenues miss analyst expectations

Avecho Biotechnology Limited Releases Results for Its Australian Phase I PK Study Characterizing the Absorption Profile of Cannabidiol from Avecho's Proprietary CBD Soft-Gel Product

Avecho Biotechnology (ASX:AVE) Is In A Good Position To Deliver On Growth Plans

Avecho Commences Enrolment for Phase I Human Clinical Trial Measuring CBD Absorption

We're Hopeful That Avecho Biotechnology (ASX:AVE) Will Use Its Cash Wisely

Non-Independent Non-Executive Director David Segal has left the company

Avecho Biotechnology Limited Completes Pharmaceutical CBD Soft-Gel Product

Full year 2020 earnings released: AU$0.002 loss per share (vs AU$0.001 profit in FY 2019)

We Think Avecho Biotechnology (ASX:AVE) Can Afford To Drive Business Growth

Full year 2020 earnings released: AU$0.002 loss per share (vs AU$0.001 profit in FY 2019)

Avecho Biotechnology Begins Human Trial on CBD Product

We're Not Very Worried About Avecho Biotechnology's (ASX:AVE) Cash Burn Rate

Avecho Biotechnology Limited Provides TPM Cannabinoid Development Program Update

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven